N-[[L-trans-3-(Ethoxycarbonyl)oxiran-2-yl]carbonyl]-L-leucyl-3-(p-hydroxyphenyl)ethylamide N-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE

CAS 262381-84-0 MFCD62381840

化学结构图

262381-84-0
SMILES:

化学属性

Mol. FormulaC20H28N2O6

别名和识别编码

Chemical NameN-[[L-trans-3-(Ethoxycarbonyl)oxiran-2-yl]carbonyl]-L-leucyl-3-(p-hydroxyphenyl)ethylamide
Chemical Name TranslationN-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE
Chemicalbook IDCB62500502
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

相关文献及参考

  • [2]. Bell-McGuinn KM, et al. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007 Aug 1;67(15):7378-85.
  • [3]. Schurigt U, et al. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem. 2008 Aug;389(8):1067-74.
  • [1]. Withana NP, et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012 Mar 1;72(5):1199-209.
  • [1]. Withana NP, et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012 Mar 1;72(5):1199-209.
  • [2]. Bell-McGuinn KM, et al. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007 Aug 1;67(15):7378-85.
  • [3]. Schurigt U, et al. Trial of t

系列性分类

  1. Medical Research Areas
  2. Metabolism
  3. Cathepsin  (组织蛋白酶)

相关产品推荐